The Treatment of Acute Optic Neuritis

References

• Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13(1):83–99. doi:10.1016/S1474-4422(13)70259-X.
   PubMed Web of Science ®Google Scholar
• Bennett JL. Optic neuritis. Continuum (Minneap Minn). 2019;25(5):1236. doi:10.1212/CON.0000000000000768.
   PubMedGoogle Scholar
• Levin MH. Demyelinating optic neuritis and its subtypes. Int Ophthalmol Clin. 2019;59(3):23–37. doi:10.1097/IIO.0000000000000278.
   PubMedGoogle Scholar
• Soelberg K, Jarius S, Skejoe HPB, et al. A population-based prospective study of optic neuritis. Multiple Sclerosis Jl. 2017;23(14):1893–1901. doi:10.1177/1352458517734070.
   PubMed Web of Science ®Google Scholar
• De Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol. 2021;269(1):1–14. doi:10.1007/s00415-020-10352-1.
   PubMed Web of Science ®Google Scholar
• Hagens MH, Burggraaff J, Kilsdonk ID, et al. Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: a MAGNIMS multicentre study. Multiple Sclerosis Jl. 2019;25(3):352–360. doi:10.1177/1352458517751647.
   PubMed Web of Science ®Google Scholar
• Prain K, Woodhall M, Vincent A, et al. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol. 2019;10:1028. doi:10.3389/fneur.2019.01028.
   PubMed Web of Science ®Google Scholar
• Ducloyer J-B, Marignier R, Wiertlewski S, Lebranchu P. Optic neuritis classification in 2021. Eur J Ophthalmol. 2021;32(2):11206721211028050. doi:10.1177/11206721211028050.
   Web of Science ®Google Scholar
• Caron-Cantin M, Cestari DM, Fortin E. Clinical and radiologic approach to ‘typical’versus antibody-related optic neuritis. Curr Opin Ophthalmol. 2019;30(6):412–417. doi:10.1097/ICU.0000000000000614.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326(9):581–588. doi:10.1056/NEJM199202273260901.
   PubMed Web of Science ®Google Scholar
• Abel A, McClelland C, Lee MS. Critical review: typical and atypical optic neuritis. Surv Ophthalmol. 2019;64(6):770–779. doi:10.1016/j.survophthal.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Winter A, Chwalisz B. MRI characteristics of NMO, MOG and MS related optic neuritis. Semin Ophthalmol. 2020;35(7–8):333–342. Taylor & Francis.
   PubMed Web of Science ®Google Scholar
• Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018;125(10):1628–1637. doi:10.1016/j.ophtha.2018.03.041.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Kezuka T, Shikishima K, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126(10):1385–1398. doi:10.1016/j.ophtha.2019.04.042.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol. 1993;111(6):773–775. doi:10.1001/archopht.1993.01090060061023.
   PubMedGoogle Scholar
• Group ONS. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115(6):1079–1082. e1075. doi:10.1016/j.ophtha.2007.08.004.
   PubMed Web of Science ®Google Scholar
• Meltzer E, Prasad S. Updates and controversies in the management of acute optic neuritis. Asia-Pac J Ophthalmol. 2018;7(4):251–256. doi:10.22608/APO.2018108.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Tobin WO, Majed M, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4–IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol. 2018;136(4):419–422. doi:10.1001/jamaophthalmol.2017.6757.
   PubMed Web of Science ®Google Scholar
• Gospe SM, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye. 2021;35(3):753–768. doi:10.1038/s41433-020-01334-8.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Takeshita T, Himori N, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020;11:11. doi:10.3389/fneur.2020.00932.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–137. doi:10.1136/jnnp-2017-316880.
   PubMed Web of Science ®Google Scholar
• Kumawat B, Choudhary R, Sharma C, Jain D, Hiremath A. Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders. Ann Indian Acad Neurol. 2019;22:389.
   PubMed Web of Science ®Google Scholar
• Deschamps R, Gueguen A, Parquet N, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol. 2016;263(5):883–887. doi:10.1007/s00415-016-8073-8.
   PubMed Web of Science ®Google Scholar
• Han M, Chen Y, Nong L, Liu Z, Hao L, Wang Z. Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis. Medicine. 2020;99(28):e21067. doi:10.1097/MD.0000000000021067.
   PubMed Web of Science ®Google Scholar
• Mori S, Kurimoto T, Ueda K, Nakamura M. Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. Jpn J Ophthalmol. 2018;62(4):525–530. doi:10.1007/s10384-018-0602-9.
   PubMed Web of Science ®Google Scholar
• Li X, Tian D-C, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020;44:102325. doi:10.1016/j.msard.2020.102325.
   PubMed Web of Science ®Google Scholar
• Lin J, Xue B, Zhu R, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42(9):1–7. doi:10.1007/s10072-021-05079-4.
   Web of Science ®Google Scholar
• Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6(4):e572. doi:10.1212/NXI.0000000000000572.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47–54. doi:10.1097/WCO.0000000000000766.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. 2019;21(1):2. doi:10.1007/s11940-019-0541-x.
   PubMed Web of Science ®Google Scholar
• Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0.
   PubMed Web of Science ®Google Scholar
• Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. 2018;75(6):690–696. doi:10.1001/jamaneurol.2018.0024.
   PubMed Web of Science ®Google Scholar